Organovo Revenues Grow 11%, Business Plan on Track in Spite of Losses Bioprinting
Organovo, the leading publicly traded bioprinting company, reported fiscal first-quarter total revenue of $1.0 million, which consisted largely of product and service revenue. Total Organovo revenues increased 11 percent versus the comparable period of fiscal 2017. Net loss was $10.1 million, or $0.10 per share, for the fiscal first quarter of 2018, as compared to $8.8 million, or $0.09 per share, for the fiscal first quarter of 2017. Negative Adjusted EBITDA(2) for the first quarter was $7.5 million, as compared to $7.1 million for the prior-year period.